Built directly into the elluminate ecosystem, the agents combine governed data with explainable intelligence to accelerate decisions

BOSTON: eClinical Solutions LLC, a global provider of digital clinical software and services, today announced elluminate AI agents – intelligence in action across the entire elluminate ecosystem. First previewed at the company’s ENGAGE conference in October, the AI agents are embedded within four key pillars of the elluminate Clinical Data Cloud®: Data Mapping, Data Review, RBQM, and Study Operations. With governed data, explainable intelligence, and human supervision, the company is shaping how the industry will operate for the next decade, powering clinical trials for transformative outcomes today and tomorrow.

Over the past decade, the average Phase III trial data volume has grown sixfold to over 5.9 million datapoints in 2025. With more data collected than ever before, eClinical Solutions has become a standard for data infrastructure and analytics, setting the groundwork for the company to capitalize on technology breakthroughs to lead the agentic revolution with speed and scale. With a decade of progress now happening in a year, the new way of discovery is AI hypotheses with human-validated breakthroughs.

eClinical Solutions’ AI agents are fueled by data products with shared context and workflows, with agentic, assistive, and task-oriented AI, and a data foundation with grounding guardrails and policies. With domain knowledge embedded across the elluminate platform, the agents are context-aware, with the ability to understand trial data. These agents support generated insights, guided exploration, and decision information in just seconds rather than hours or days. Trial leaders will soon be able to leverage these agents within the following areas of the elluminate platform:

• Data Mapping: Transforming the path from raw to ready by supporting spec generation, mapping transformation, validation, and code checks.
• Data Review: Accelerating data understanding and review through visualization explanation, anomaly review, and semi-automated issue creation.
• RBQM: Enhancing quality and oversight by drafting risk statements, tracking KRIs, surfacing meaningful signals, and recommending mitigations.
• Study Operations: Reducing setup time and improving transparency by interpreting protocols, configuring studies, and analyzing operational bottlenecks.

“Over the last decade, eClinical Solutions has worked to address the historical challenge of data chaos with harmonized, governed data and intelligent data products, offering the industry a solution with our elluminate platform,” said Raj Indupuri, CEO and co-founder of eClinical Solutions. “The last 10+ years of innovation uniquely set us up to power the future. Today, we see an opportunity to evolve our data cloud into a data intelligence platform with our elluminate agents acting as partners across the clinical development value chain to learn fast and act with humans in the loop. As cycle times remain the currency of drug development, we are proud to be leaders bending the clinical development curve with data and AI.”

The first elluminate agents will be available in early 2026, and will follow a phased approach across the products. To learn how elluminate’s AI and agentic capabilities can support your trials with speed and scale, visit: eclinicalsol.com/elluminate-ai-agents/

About eClinical Solutions LLC
eClinical Solutions’ industry-leading data & analytics platform, elluminate®, and biometrics services experts help biopharma researchers at large, mid-size, and emerging life sciences organizations develop tomorrow’s breakthroughs with today’s resources. eClinical is a privately-held, purpose-driven company with a global workforce and winner of two 2025 Top Workplaces Culture Excellence Awards, the 2024 Top Workplaces USA Award, and Great Place To Work® India Certification™. Learn more at www.eclinicalsol.com and follow eClinical Solutions on LinkedIn.

Fonte: Business Wire